Stifel Nicolaus Sticks to Their Hold Rating for Denali Therapeutics (DNLI)

In a report released on May 10, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Denali Therapeutics (DNLI – Research Report), with a price target of $22.00. The company’s shares closed last Friday at $18.31.

Matteis covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, BioMarin Pharmaceutical, and Alkermes. According to TipRanks, Matteis has an average return of 6.8% and a 45.29% success rate on recommended stocks.

Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.50.

Based on Denali Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $119.47 million. In comparison, last year the company earned a revenue of $3.56 million and had a GAAP net loss of $103.3 million

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DNLI in relation to earlier this year. Most recently, in February 2024, Alexander O. Schuth, the COFO and Secretary of DNLI bought 50,000.00 shares for a total of $34,000.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Denali Therapeutics (DNLI) Company Description:

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.